An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry-Reference-Cited by-同舟云学术

An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry

Published:2020-06-16 Issue:9 Volume:59 Page:1123-1130
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Pouwels Xavier G. L. V.¹²³^ORCID,Ramaekers Bram L. T.¹,Geurts Sandra M. E.³⁴,Erdkamp Frans⁵,Vriens Birgit E. P. J.⁶,Aaldering Kirsten N. A.⁷,van de Wouw Agnes J.⁸,Dercksen M. W.⁹,Smilde Tineke J.¹⁰,Peters Natascha A. J. B.¹¹,van Riel J. M. G. H.¹²,Pepels Manon J.¹³,Heijnen-Mommers Jose³⁴,Tjan-Heijnen Vivianne C. G.³⁴^ORCID,de Boer Maaike³⁴,Joore Manuela A.¹²

Affiliation:

1. Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre +, Maastricht, The Netherlands;

2. Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands;

3. School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands;

4. Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Centre +, Maastricht, The Netherlands;

5. Department of Internal Medicine, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands;

6. Department of Internal Medicine, Catharina Hospital, Eindhoven, The Netherlands;

7. Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands;

8. Department of Internal Medicine, VieCuri Medical Center, Venlo, The Netherlands;

9. Department of Internal Medicine, Máxima Medical Centre, Eindhoven, The Netherlands;

10. Department of Internal Medicine, Jeroen Bosch Hospital, Hertogenbosch, The Netherlands;

11. Department of Internal Medicine, Sint Jans Gasthuis, Weert, The Netherlands;

12. Department of Internal Medicine, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands;

13. Department of Internal Medicine, Elkerliek Hospital, Helmond, The Netherlands

Publisher

Informa UK Limited

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2020.1775289

Reference35 articles.

1. College van Zorgverzekering. Eribulin (Halaven) bij lokaal gevorderde of gemetastaseerde borstkanker. 2013.

2. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

3. Zorginstituut Nederland. Beoordeling dure specialistische geneesmiddelen [cited 2019 Oct 11]. Available from: https://www.zorginstituutnederland.nl/over-ons/werkwijzen-en-procedures/adviseren-over-en-verduidelijken-van-het-basispakket-aan-zorg/beoordeling-van-geneesmiddelen/beoordeling-dure-specialistische-geneesmiddelen

4. null

5. The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands;Scientific Reports;2023-02-09

2. Budget impact analysis of breast cancer medications: a systematic review;Journal of Pharmaceutical Policy and Practice;2022-12-29

3. Cost-utility analysis of eribulin versus capecitabine in HER-2 negative advanced or metastatic breast cancer in China;2022-12-02

4. Correction;Acta Oncologica;2021-03-01